Literature DB >> 32427530

Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.

Virginia Knez1, Liming Bao1,2, Billie Carstens2, Xiayuan Liang1,3.   

Abstract

Although considered the same disease by 2016 WHO Classification, B-ALL and B-LBL show different clinicobiologic behavior, with B-ALL manifesting as disseminated disease and B-LBL as a localized mass. Distinction between the two is based on an arbitrary cutoff of 25% bone marrow involvement. We reviewed clinical, immunophenotypic, and cytogenetic data in B-lymphoblastic neoplasms of childhood to explain the differences. Performing a retrospective review of 126 cases of B-ALL and 18 cases of B-LBL in patients ≤18 years, revealed the following significant differences: younger age of presentation for leukemia; increased cytogenetic abnormalities in leukemia than lymphoma, specifically increased recurrent genetic abnormalities, with the exception of ploidy aberrancy; and the observation that unfavorable recurrent genetic abnormalities occurred in B-ALL and only favorable abnormalities in B-LBL. Down syndrome presented with leukemia only. Findings demonstrated that pediatric B-ALL and B-LBL exhibit dissimilar genomic profiles, suggesting possible differences in pathogenesis between the two closely-related neoplasms.

Entities:  

Keywords:  Leukemia; acute leukemia; acute lymphoblastic leukemia; lymphoblastic lymphoma

Mesh:

Year:  2020        PMID: 32427530     DOI: 10.1080/10428194.2020.1761970

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement.

Authors:  Emma Kroeze; Laura Arias Padilla; Max Bakker; Judith M Boer; Melanie M Hagleitner; Birgit Burkhardt; Takeshi Mori; Andishe Attarbaschi; Jaime Verdú-Amorós; Marta Pillon; Liliya Anderzhanova; Edita Kabíčková; Alan K S Chiang; Rejin Kebudi; Karin Mellgren; Jelena Lazic; Janez Jazbec; Jules P P Meijerink; Auke Beishuizen; Jan L C Loeffen
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.